OverviewSuggest Edit

Horizon Discovery is a revenue-generating life science group supplying research tools to organizations engaged in translational genomics research and the development of personalized medicines. Horizon serves various organizations including major pharmaceutical, biotechnology, and diagnostic companies as well as leading academic research centers. The Group core capabilities are built around its proprietary translational genomics platform, a high-precision and flexible suite of gene editing tools able to alter almost any endogenous gene sequence of human or mammalian cell lines. Horizon offers a portfolio of products, almost all of which are based on the application of gene editing to generate cell lines that accurately model the disease-causing mutations found in genetically based diseases. These ‘patients-in-a-test-tube’ are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments. In addition, it provides custom cell line and in vivo model generation services for research and bioproduction applications, quantitative molecular reference standards, in vivo disease models, and contract research and custom screening services.

HQWaterbeach, GB
Employee Ratings3.1

Latest Updates

Employees (est.) (Dec 2018)398
Job Openings4
Revenue (FY, 2018)£58.7 M(+69%)
Share Price (Sept 2020)£1 (+2%)
Cybersecurity ratingBMore

Key People/Management at Horizon Discovery

Darrin Disley

Darrin Disley

Richard Vellacott

Richard Vellacott

Chief Financial Officer & Deputy Chief Executive Officer
Terry Pizzie

Terry Pizzie

Head of Commercial Operations
Heather Hayes

Heather Hayes

Head of Human Resources
Jurgen Harter

Jurgen Harter

Global Head of IT & Informatics
Jon Moore

Jon Moore

Chief Scientific Officer, Head of Translational Science
Show more

Horizon Discovery Office Locations

Horizon Discovery has offices in Waterbeach, Boyertown, Lafayette and St. Louis
Waterbeach, GB (HQ)
Cambridge Research Park Beach Dr
Boyertown, US
Boyertown, PA 19512, USA
Lafayette, US
2650 Crescent Dr #100
St. Louis, US
2033 Westport Center Dr
Show all (4)

Horizon Discovery Financials and Metrics

Horizon Discovery Revenue

Embed Graph
View revenue for all periods
Horizon Discovery's revenue was reported to be £58.73 m in FY, 2018

Revenue (FY, 2018)


Gross profit (FY, 2018)


Gross profit margin (FY, 2018), %


Net income (FY, 2018)


EBITDA (FY, 2018)


EBIT (FY, 2018)


Market capitalization (14-Sept-2020)


Closing stock price (14-Sept-2020)


Cash (31-Dec-2018)

Horizon Discovery's current market capitalization is £156.4 m.
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018



Revenue growth, %


Cost of goods sold


Gross profit

GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018



Accounts Receivable




Current Assets

GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income


Cash From Operating Activities


Cash From Financing Activities


Net Change in Cash

GBPFY, 2013

Financial Leverage

1.4 x
Show all financial metrics

Horizon Discovery Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Horizon Discovery Online and Social Media Presence

Embed Graph

Horizon Discovery News and Updates

Horizon Discovery Group plc: Pre-Close Trading Update

Horizon Discovery Group plc

Genome Editing - The World Market (2019-2025): ThermoFisher Scientific, GenScript, Sangamo Therapeutics, Lonza Group, and Horizon Discovery Group are Leading

DUBLIN, March 27, 2019 /PRNewswire/ -- The "Global Genome Editing Market - Drivers, Restraints, Opportunities, Trends, and Forecast, 2019-2025" report has been added to ResearchAndMarkets.com's offering. The Genome Editing Market is Expected to Witness a CAGR of 14.4% to Reach $8.3...

Activist ValueAct raises stake in Horizon Discovery

Activist hedge fund ValueAct Capital has nearly doubled its stake in Horizon Discovery Group , buying an additional 7.5 million shares from Woodford Investment Management.

Horizon Discovery Group Plc: Interim Results for the Six Months Ended 30 June 2018

HORIZON DISCOVERY GROUP PLC (“Horizon”, “the Group” or “the Company”)

Horizon Discovery Blogs

You've done your CRISPR transfection... what's next?

CRISPR-Cas9 is a very versatile tool to discover more about your pathway or gene of interest. After all that hard work editing your cell line, you want to have the confidence to rely on your new research model. So, how do you verify your cell line is what you expect it to be? There are …

Using Cell Lines for Antibody Validation – what you need to know to get started

CRISPR-edited Cell Lines are a great tool to validate your antibodies before you start your experiments. They ensure you are using high quality reagents, so you can be confident in your results. We explain how you can use Cell Lines for validation, the challenges to be aware of and how w…

Major study uses Horizon's HAP1 cell lines to screen thousands of BRCA1 mutations

A major study has been undertaken to gain a better understanding of thousands of mutations in the BRCA1 gene – a key gene in breast and ovarian cancers.  Published in Nature this month, the study by the Department of Genome Sciences at the University of Washington School of Medicine, set out to ana…

How to... find your ideal cell line model

With over 25,000 individual Cell Lines in our new Express Catalog, we want to give you a helping hand with finding the ideal Cell Line Model for your research.  Using our new downloadable catalog, you can now search, filter and browse through our online cell model offering. There are tw…

5 ways to validate and extend your research with Knockout Cell Lines

CRISPR technology now allows genes and molecular pathways to be examined with greater definition. We look at how knockout cell lines, either together with gene rescue and replication of disease mutations or as an independent cell model, can be used to validate your research and extend yo…
Show more

Horizon Discovery Frequently Asked Questions

  • When was Horizon Discovery founded?

    Horizon Discovery was founded in 2005.

  • Who are Horizon Discovery key executives?

    Horizon Discovery's key executives are Darrin Disley, Richard Vellacott and Terry Pizzie.

  • How many employees does Horizon Discovery have?

    Horizon Discovery has 398 employees.

  • What is Horizon Discovery revenue?

    Latest Horizon Discovery annual revenue is £58.7 m.

  • What is Horizon Discovery revenue per employee?

    Latest Horizon Discovery revenue per employee is £147.6 k.

  • Who are Horizon Discovery competitors?

    Competitors of Horizon Discovery include Actinium Pharmaceuticals, ArcanaBio and Genematrix.

  • Where is Horizon Discovery headquarters?

    Horizon Discovery headquarters is located at Cambridge Research Park Beach Dr, Waterbeach.

  • Where are Horizon Discovery offices?

    Horizon Discovery has offices in Waterbeach, Boyertown, Lafayette and St. Louis.

  • How many offices does Horizon Discovery have?

    Horizon Discovery has 4 offices.